Clinical trial
A Phase 3 Open Label Safety Study of A-101 Topical Solution for the Treatment of Common Warts
NCT03812510 is registered in ClinicalTrials.gov with Aclaris Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Open Label Safety Study of A-101 Topical Solution for the Treatment of Common Warts
- Lead sponsor
- Aclaris Therapeutics, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 7, 2019
- Completion date
- December 20, 2019
- Enrollment
- 426 (actual)
- Sites
- 46
Conditions
As the registry lists them; a condition with its own page is linked.
common wart